Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - NexMed, Inc. (NasdaqNM:NEXM)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Recent Events
Aug 14Price hit new 52-week low ($2.50)
Aug 13Earnings Announcement
Location
350 Corporate Boulevard
Robbinsville, NJ 08691
Phone: (609) 208-9688
Fax: (609) 208-1868
Email: csouthworth@rubensteinpr.com
Employees (last reported count): 51
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 38%
·Over the last 6 months:
 · one insider buy; 10.0K shares (0.1% of insider shares)
 · one insider sell; 3,000  shares
·Institutional: 16% (25% of float)
(24 institutions)
·Net Inst. Buying: 760.0K shares (+15.91%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
NexMed, Inc. is a pharmaceutical and medical technology company. The Company develops and commercializes therapeutic products based on proprietary delivery systems. The Company is focusing its efforts on new and patented pharmaceutical products based on a penetration-enhancement, topical-delivery technology known as NexACT. The Company is applying the NexACT technology to Alprox-TD, an alprostadil cream for the treatment of male erectile dysfunction and Femprox, also an alprostadil-based cream, for the treatment of female sexual arousal disorder.
More from Market Guide: Expanded Business Description

Financial Summary
NexMed, Inc. is a medical and pharmaceutical technology company focused on developing and commercializing topical alprostadil treatments that incorporate a new penetration enhancement technology, and the Viratrol device. For the six months ended 6/30/01, the Company reported no revenue. Net loss rose 83% to $6.8 million. Results reflect costs related to the scaling-up of U.S. clinical trials and additional research personnel.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Y. Joseph Mo, Ph.D., 53
Chairman, Pres and CEO
$317K$1.4M
James Yeager, Ph.D., 54
Director, VP, R&D and Bus. Devel.
255K--  
Vivian Liu, 39
VP- Corp. Affairs, CFO, Sec.
191K461K
Kenneth Anderson, 54
VP, Commercial Devel.
29K--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:NEXMAs of 31-Aug-2001
Price and Volume
52-Week Low
on 14-Aug-2001
$2.50 
Recent Price$3.34 
52-Week High
on 5-Oct-2000
$20.625
Beta0.43 
Daily Volume (3-month avg)44.6K
Daily Volume (10-day avg)24.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y]
52-Week Change-76.7%
52-Week Change
relative to S&P500
-68.7%
Share-Related Items
Market Capitalization$85.2M
Shares Outstanding25.5M
Float15.8M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$1.30 
Earnings (ttm)-$0.49 
Earnings (mrq)-$0.14 
SalesN/A 
Cash (mrq)$1.10 
Valuation Ratios
Price/Book (mrq)2.57 
Price/EarningsN/A 
Price/SalesN/A 
Income Statements
Sales (ttm)$0 
EBITDA (ttm)-$12.7M
Income available to common (ttm)-$11.8M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-34.25%
Return on Equity (ttm)-35.15%
Financial Strength
Current Ratio (mrq)26.02 
Debt/Equity (mrq)0 
Total Cash (mrq)$27.8M
Short Interest
As of 8-Aug-2001
Shares Short9,000 
Percent of Float0.1%
Shares Short
(Prior Month)
9,000 
Short Ratio0.18 
Daily Volume51.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Some event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.